GlassScriptPhysician profile
Madison Delk
NPI 1154838514
$2,088.32
in general payments reported to CMS, 2019-2025
28 companies · $780 in 2025
The $780 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $168 · 2023: $355 · 2024: $454 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.27 | 2021-2025 | |
| Novo Nordisk INC | $266.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $228.57 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.80 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $132.37 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $102.48 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $99.21 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Vanda Pharmaceuticals INC. | $80.39 | 2024-2025 | Hetlioz, Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $77.56 | 2024-2025 | |
| Axsome Therapeutics, INC. | $77.53 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $51.66 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $43.56 | 2023-2024 | Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $36.70 | 2021-2022 | |
| Dexcom, INC. | $36.06 | 2021-2022 | |
| Ortho-Clinical Diagnostics, INC. | $28.60 | 2024 | Sofia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $27.35 | 2025 | Tonmya |
| Corium, LLC | $26.12 | 2023 | Azstarys |
| Merit Medical Systems INC | $25.44 | 2025 | Savi Scout |
| Inogen, INC. | $22.79 | 2022 | |
| Esperion Therapeutics, INC. | $19.62 | 2024 | Nexletol |
| Genzyme Corporation | $19.31 | 2022 | |
| Philips North America LLC | $17.98 | 2023 | |
| Phadia US INC. | $15.88 | 2022 | |
| Clarus Therapeutics INC. | $15.40 | 2021 | |
| Amgen INC. | $14.78 | 2023 | Otezla, Repatha |
| Abbott Laboratories | $13.98 | 2021 | |
| Eisai INC. | $13.60 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Delk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.